Literature DB >> 32764101

Association of epileptiform abnormalities and seizures in Alzheimer disease.

Alice D Lam1, Rani A Sarkis2, Kyle R Pellerin2, Jin Jing2, Barbara A Dworetzky2, Daniel B Hoch2, Claire S Jacobs2, Jong Woo Lee2, Daniel S Weisholtz2, Rodrigo Zepeda2, M Brandon Westover2, Andrew J Cole2, Sydney S Cash2.   

Abstract

OBJECTIVE: To examine the relationship between scalp EEG biomarkers of hyperexcitability in Alzheimer disease (AD) and to determine how these electric biomarkers relate to the clinical expression of seizures in AD.
METHODS: In this cross-sectional study, we performed 24-hour ambulatory scalp EEGs on 43 cognitively normal elderly healthy controls (HC), 41 participants with early-stage AD with no history or risk factors for epilepsy (AD-NoEp), and 15 participants with early-stage AD with late-onset epilepsy related to AD (AD-Ep). Two epileptologists blinded to diagnosis visually reviewed all EEGs and annotated all potential epileptiform abnormalities. A panel of 9 epileptologists blinded to diagnosis was then surveyed to generate a consensus interpretation of epileptiform abnormalities in each EEG.
RESULTS: Epileptiform abnormalities were seen in 53% of AD-Ep, 22% of AD-NoEp, and 4.7% of HC. Specific features of epileptiform discharges, including high frequency, robust morphology, right temporal location, and occurrence during wakefulness and REM, were associated with clinical seizures in AD. Multiple EEG biomarkers concordantly demonstrated a pattern of left temporal lobe hyperexcitability in early stages of AD, whereas clinical seizures in AD were often associated with bitemporal hyperexcitability. Frequent small sharp spikes were specifically associated with epileptiform EEGs and thus identified as a potential biomarker of hyperexcitability in AD.
CONCLUSION: Epileptiform abnormalities are common in AD but not all equivalent. Specific features of epileptiform discharges are associated with clinical seizures in AD. Given the difficulty recognizing clinical seizures in AD, these EEG features could provide guidance on which patients with AD are at high risk for clinical seizures.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32764101      PMCID: PMC7713786          DOI: 10.1212/WNL.0000000000010612

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  47 in total

Review 1.  Seizures and epilepsy in Alzheimer's disease.

Authors:  Daniel Friedman; Lawrence S Honig; Nikolaos Scarmeas
Journal:  CNS Neurosci Ther       Date:  2011-06-07       Impact factor: 5.243

2.  Intracranial EEG substrates of scalp EEG interictal spikes.

Authors:  James X Tao; Amit Ray; Susan Hawes-Ebersole; John S Ebersole
Journal:  Epilepsia       Date:  2005-05       Impact factor: 5.864

Review 3.  Network abnormalities and interneuron dysfunction in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Rev Neurosci       Date:  2016-11-10       Impact factor: 34.870

4.  Epileptic Prodromal Alzheimer's Disease, a Retrospective Study of 13 New Cases: Expanding the Spectrum of Alzheimer's Disease to an Epileptic Variant?

Authors:  Benjamin Cretin; François Sellal; Nathalie Philippi; Olivier Bousiges; Laure Di Bitonto; Catherine Martin-Hunyadi; Frederic Blanc
Journal:  J Alzheimers Dis       Date:  2016-04-18       Impact factor: 4.472

5.  Interrater Reliability of Experts in Identifying Interictal Epileptiform Discharges in Electroencephalograms.

Authors:  Jin Jing; Aline Herlopian; Ioannis Karakis; Marcus Ng; Jonathan J Halford; Alice Lam; Douglas Maus; Fonda Chan; Marjan Dolatshahi; Carlos F Muniz; Catherine Chu; Valeria Sacca; Jay Pathmanathan; WenDong Ge; Haoqi Sun; Justin Dauwels; Andrew J Cole; Daniel B Hoch; Sydney S Cash; M Brandon Westover
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

6.  Temporal intermittent rhythmic delta activity in electroencephalograms.

Authors:  M M Normand; Z K Wszolek; D W Klass
Journal:  J Clin Neurophysiol       Date:  1995-05       Impact factor: 2.177

7.  Incidence of new-onset seizures in mild to moderate Alzheimer disease.

Authors:  Michael C Irizarry; Shelia Jin; Feng He; Jennifer A Emond; Rema Raman; Ronald G Thomas; Mary Sano; Joseph F Quinn; Pierre N Tariot; Douglas R Galasko; Lianna S Ishihara; John G Weil; Paul S Aisen
Journal:  Arch Neurol       Date:  2012-03

8.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Authors:  Pascal E Sanchez; Lei Zhu; Laure Verret; Keith A Vossel; Anna G Orr; John R Cirrito; Nino Devidze; Kaitlyn Ho; Gui-Qiu Yu; Jorge J Palop; Lennart Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

9.  Dementia and adult-onset unprovoked seizures.

Authors:  D C Hesdorffer; W A Hauser; J F Annegers; E Kokmen; W A Rocca
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

10.  Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.

Authors:  Arnold Bakker; Gregory L Krauss; Marilyn S Albert; Caroline L Speck; Lauren R Jones; Craig E Stark; Michael A Yassa; Susan S Bassett; Amy L Shelton; Michela Gallagher
Journal:  Neuron       Date:  2012-05-10       Impact factor: 17.173

View more
  19 in total

Review 1.  Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities.

Authors:  Shaomin Li; Andrew M Stern
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

2.  Early death in a mouse model of Alzheimer's disease exacerbated by microglial loss of TAM receptor signaling.

Authors:  Youtong Huang; Greg Lemke
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-03       Impact factor: 12.779

Review 3.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

4.  APOE4 Promotes Tonic-Clonic Seizures, an Effect Modified by Familial Alzheimer's Disease Mutations.

Authors:  Lorissa Lamoureux; Felecia M Marottoli; Kuei Y Tseng; Leon M Tai
Journal:  Front Cell Dev Biol       Date:  2021-03-16

5.  Dementia with non-convulsive seizures: a case report.

Authors:  Yu-Shiue Chen; Tsang-Shan Chen; Chin-Wei Huang
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

Review 6.  Electrophysiological Biomarkers of Epileptogenicity in Alzheimer's Disease.

Authors:  Tingting Yu; Xiao Liu; Jianping Wu; Qun Wang
Journal:  Front Hum Neurosci       Date:  2021-11-30       Impact factor: 3.169

7.  Preclinical evaluation of drug treatment options for sleep-related epileptiform spiking in Alzheimer's disease.

Authors:  Nanxiang Jin; Irina Gureviciene; Aysu Naz Atalay; Sara Häkli; Sofya Ziyatdinova; Heikki Tanila
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-05

8.  Advancing towards Ubiquitous EEG, Correlation of In-Ear EEG with Forehead EEG.

Authors:  Swati Mandekar; Abigail Holland; Moritz Thielen; Mehdi Behbahani; Mark Melnykowycz
Journal:  Sensors (Basel)       Date:  2022-02-17       Impact factor: 3.576

9.  The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease.

Authors:  Sarah Gourmaud; David A Stewart; David J Irwin; Nicholas Roberts; Aaron J Barbour; Grace Eberwine; William T O'Brien; Robert Vassar; Delia M Talos; Frances E Jensen
Journal:  Brain       Date:  2022-03-29       Impact factor: 15.255

10.  Night Watch on the Titanic: Detecting Early Signs of Epileptogenesis in Alzheimer Disease.

Authors:  Alice D Lam; Jeffrey Noebels
Journal:  Epilepsy Curr       Date:  2020-10-20       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.